ENVERIC BIOSCI.INC.DL-01
Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the trea… Read more
ENVERIC BIOSCI.INC.DL-01 (SLZA) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, ENVERIC BIOSCI.INC.DL-01 (SLZA) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
ENVERIC BIOSCI.INC.DL-01 - Net Assets Trend (None–None)
This chart illustrates how ENVERIC BIOSCI.INC.DL-01's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for ENVERIC BIOSCI.INC.DL-01 (None–None)
The table below shows the annual net assets of ENVERIC BIOSCI.INC.DL-01 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to ENVERIC BIOSCI.INC.DL-01's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
ENVERIC BIOSCI.INC.DL-01 Competitors by Market Cap
The table below lists competitors of ENVERIC BIOSCI.INC.DL-01 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Blue Dolphin Energy Co
OTCQX:BDCO
|
$3.39 Million |
|
TRIBOO S.P.A.
F:0T6
|
$3.39 Million |
|
PATRYS Ltd
AU:PAB
|
$3.40 Million |
|
KYM Holdings Bhd
KLSE:8362
|
$3.40 Million |
|
Realfiction Holding AB
ST:REALFI
|
$3.39 Million |
|
Ecolomondo Corporation
OTCQB:ECLMF
|
$3.39 Million |
|
Dominion Minerals Ltd
AU:DLM
|
$3.39 Million |
|
WF Holding Limited Ordinary Shares
NASDAQ:WFF
|
$3.39 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ENVERIC BIOSCI.INC.DL-01's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares ENVERIC BIOSCI.INC.DL-01's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently ENVERIC BIOSCI.INC.DL-01 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares ENVERIC BIOSCI.INC.DL-01's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ENVERIC BIOSCI.INC.DL-01 (SLZA) | €- | N/A | N/A | $3.39 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |